United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...

United Therapeutics’ xenokidney ... today’s milestone reinforces that we are on track to fulfill our ultimate mission to create an unlimited supply of transplantable organs and organ ...

United Therapeutics Corp. (NASDAQ ... The FDA’s sign-off “represents a significant step forward in our relentless mission to expand the availability of transplantable organs,” Leigh Peterson ...

United Therapeutics Corporation (Nasdaq ... of a xenokidney represents a significant step forward in our relentless mission to expand the availability of transplantable organs,” said Leigh ...

United Therapeutics's approval, announced Monday, allows the company to advance its technology toward a licensed product if ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND ...